LOGIN-VSI
29.7.2020 14:32:11 CEST | Business Wire | Press release
HTG – Howell Technology Group, the specialised supplier of innovative IT and security solutions, today announced that it has signed a supplier agreement with Login VSI , the company dedicated to maximising the end-user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005078/en/
Delivered through a customer-centric approach, HTG’s professional and trusted IT consulting services enables customers to operate sustainably and achieve efficiencies gained from transformation of their IT environments to modern, cloud-based workspaces.
This partnership will focus on the provision of specialist solutions and services as part of the ecosystem for Windows Virtual Desktop (WVD). Working closely with Microsoft as a Gold partner, HTG is already deploying WVD to some impressive accounts as a cloud-based, remote working solution. Adding Login VSI to this mix represents an opportunity for HTG to join forces with the market leader in synthetic user testing.
Kevin Howell, CTO, HTG said, “Sizing end-user compute solutions to deliver optimal user experience and performance can be complex. Using Login VSI allows us to deliver our services in a performant and efficient manner.”
For Login VSI, this partnership represents the opportunity to work with a highly regarded consultant. Using their specialised skills, HTG will be able to efficiently deploy Login Enterprise into their customer base – delivering to them application compatibility testing, load testing, as well as performance and availability testing in a single platform.
Since the onset of COVID, there has been an increased demand for enterprise IT organisations to support a global remote working model. Testing of a scaled-up remote infrastructure has therefore become critical. Login VSI provides comprehensive testing and validation of the entire technology stack, from the core to the endpoint. It maximises the scalability and availability of applications and virtual desktop environments, including cloud. Login Enterprise, Login VSI’s flagship product, enables enterprises to quickly identify potential performance or availability issues by measuring and comparing application load times and application responsiveness. It is this expertise that will provide added value to HTG’s services within the digital workspace and especially as part of the WVD ecosystem.
Graham Wight, CEO, HTG commented: “We are excited about the opportunity to work with Login VSI. With the recent shift in demand for technologies that enable the smooth and secure transition to remote working, there is a greater need for performance and availability testing. The addition of this service under the partnership can only enhance and add value to the services we provide our customers.”
“We are excited about the opportunity to work with HTG,” said Eric-Jan van Leeuwen, CEO of Login VSI. “Given the global shift to remote working, there is a greater need for performance and availability testing, in order to ensure business continuity. With HTG’s superior knowledge of the WVD market and the unrivalled experience they have, we believe this is the beginning of a long-lasting relationship.”
About HTG
HTG is a leading global IT solutions company offering a range of disruptive technologies and best in class products. We work closely with customers from a wide range of industries to enable efficiencies through transformation of their IT environments and help simplify the way our IT services are delivered to them. Our digital knowledge and expertise in the latest technologies enables us to help our customers define their digital vision and strategic roadmap, delivering real and impactful change.
For further information please visit www.htguk.com or contact us on 0191 481 3446 .
About Login VSI
Login VSI is the only solution in the market guaranteed to maximize the end-user experience for digital workspaces. We reduce risk and ensure business continuity by safeguarding application and desktop performance. We do this using synthetic users to automatically test and validate the impact of change in physical, virtual and cloud-based workspaces.
Our flagship product, Login Enterprise integrates application compatibility testing, load testing, as well as performance & availability testing into a single platform. Login Enterprise also includes standard “out-of-the-box” application template workloads. Login VSI has over 400 customers in 50 countries. For more information, visit www.loginvsi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom